Pharma Pulse 6/27/25: How AI and Machine Learning Can Improve Patient Reported Outcomes in Clinical Trials; The Role of Patient Advocacy in Shaping AbbVie's Cancer Therapies
In an interview with Applied Clinical Trials, Brian Ongioni, chief product officer at uMotif, explained how the company integrates patient and site feedback early in the development process to improve the usability and regulatory strength of digital health tools, and shared how AI and machine learning could further enhance patient-reported outcomes by amplifying patient voices and streamlining trial workflows.
The Role of Patient Advocacy in Shaping AbbVie's Cancer Therapies
In an interview with Pharmaceutical Executive, Pedro Valencia, VP of asset strategy leadership, oncology, at AbbVie, emphasized the company’s commitment to incorporating patient advocacy into early development decisions—particularly in solid tumors—highlighting how feedback from advocacy groups helps shape AbbVie’s oncology pipeline and advance therapies that address both clinical outcomes and meaningful quality-of-life benefits.
Sticking With It: A Meta-Review of Anti-Dementia Medication Use and Adherence
A recent meta-analysis of nearly 700,000 patients found that persistence with anti-dementia drugs drops significantly over time, with only about half of patients remaining on treatment at 12 months, highlighting the need for standardized reporting and targeted interventions to improve long-term adherence and patient outcomes.
Q&A: Creating a Pharmacy Where Technicians Can Thrive
In a recent interview with Drug Topics, Taylor Watterson, PharmD, PhD, emphasized that creating a pharmacy where technicians can thrive starts with recognizing their critical role in operations, offering career advancement, fair compensation, and involving them in decision-making—especially in independent pharmacies where their contributions are already deeply valued.
In a recent discussion on Oncology Unplugged, Chandler Park and Midhun Malla explored how treatment for metastatic colorectal cancer is becoming increasingly personalized, emphasizing the importance of early molecular profiling and tailoring therapies for BRAF V600E–mutant and HER2-positive tumors based on emerging trial data, tumor sidedness, and evolving real-world practices.
